Advertisement

Therapie der hepatischen Enzephalopathie

  • E.-H. Egberts

Zusammenfassung

Ein Zusammenhang zwischen geistig-seelischen Funktionen und der Leber wurde bereits von den Babyloniern und im alten China um die Jahrtausendwende vor Christi angenommen. Hippokrates beschrieb ein delirantes Zustandsbild, vermutlich bei fulminanter Hepatitis. Bei der von Galen vertretenen „Säftelehre“ kam einer gestörten Lebersekretion eine große Bedeutung für psychopathologische Veränderungen zu, dies spiegelt sich in auch heute noch alltäglichen Redewendungen wieder. Aber erst im 18. Jahrhundert beginnen eingehendere Beschreibungen und Untersuchungen der neuropsychiatrischen Symptomatik bei Lebererkrankungen [16], und ab Mitte der 50er Jahre werden wirksame Behandlungsmaßnahmen entwickelt.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Abouna GM, Korkley JR, Hull GJ, Ashcroft T, Kerr NNS (1969) Treatment of hepatic coma by extracorporeal pig-liver perfusion. Lancet 1: 64–68Google Scholar
  2. 2.
    Abouna GM, Serrou B, Boehmig HG, Amemiga H, Martineau G (1970) Long-term hepatic support by intermittent multispecies liver perfusions. Lancet II: 391 – 396Google Scholar
  3. 2a.
    Abramsky O, Goldschmidt Z (1974) Treatment and prevention of acute hepatic encephalopathy by intravenous levodopa. Surgery 75: 188–193PubMedGoogle Scholar
  4. 3.
    Adams RD, Foley JM (1953) The disorder of movement in the more common varieties of liver disease. Electroencephalogr Clin Neurophysiol 3 [Suppl]: 51Google Scholar
  5. 4.
    Agishi T, Yamashita N, Ota K (1980) Clinical results of direct charcoal haemoperfusion for endogenous and exogenous intoxication. In: Sideman S, Chang TMS (eds) Haemoperfusion kidney and liver support and detoxification. Hemisphere, Washington, pp 255–273Google Scholar
  6. 5.
    Amano I, Kano H, Takahira H et al. (1978) Hepatic assist system using bead-type charcoal. In: Chang, TMS (ed) Artificial kidney, artificial liver and artificial cells. Plenum Press, New York, pp 89–98Google Scholar
  7. 6.
    Arias J, Alsasua A, Estebanez E, Lopes-Sanches ML, Arias JI, Duran M, Garcia de Jalon PD, Duran Sacristan H (1982) Efecto de Levodopa sobre los niveles cerebrales de noradrenaline, dopamine y acido homovainillico en la encefalopatia portosistemica experimental. Rev Clin Esp 166: 221–224Google Scholar
  8. 7.
    Atterbury CE, Maddrey WC, Conn HO et al. (1978) Lactulose and neomycinsorbital in the treatment of acute portal-systemic encephalopathy: a double blind controlled clinical trail. Gastroenterology 23: 389–406Google Scholar
  9. 8.
    Baldessarini RJ, Fischer JE (1973) Serotonin metabolism in rat brain after surgical diversion of the portal venous circulation. Nature (New Biol) 245: 25–28Google Scholar
  10. 9.
    Baltzer G, Dölle W, Bähr U et al. (1971) Austauschtransfusion bei akutem Leberversagen. Dtsch Med Wochenschr 96: 1329–1333PubMedGoogle Scholar
  11. 10.
    Bartels O, Neidhardt B, Neidhardt M et al. (1977) Untersuchungen und Erfahrungen mit der Kohle-Haemoperfusion bei Leberkoma. In: Demling L, Bartels O (Hrsg) Entgiftung mit Haemoperfusion. Bundernagel Freiburg, S 119–131Google Scholar
  12. 11.
    Bauer AGC, Wilson JHP, Lamberts SWJ, Blom W (1983) Hyperprolactinemia in hepatic encephalopathy: the effect of infusion of an amino acid mixture with excess branched chain amino acids. Hepato Gastroenterol 30: 174–177Google Scholar
  13. 12.
    Berger RL, Liversage RM, Chalmers TC, Graham JH, McGoldrick DM, Stohlman F (1966) Exchange transfusion in the treatment of fulminating hepatitis. N Engl J Med 274: 497–499PubMedGoogle Scholar
  14. 13.
    Bessman AN, Mirick GS (1958) Blood ammonia levels following the ingestion of casein and whole blood. J Clin Invest 37: 990–998PubMedGoogle Scholar
  15. 14.
    Bihari D, Hughes RD, Gimson AES et al. (1983) Effects of serial resin haemoperfusion in fulminant hepatic failure. Int J Artif Organs 6: 299–302PubMedGoogle Scholar
  16. 15.
    Bianchi L (1977) Leberinsuffizienz und Leberkoma — pathologisch-anatomische Substrate. Leber Magen Darm 7: 221–226PubMedGoogle Scholar
  17. 16.
    Binder H (1981) Die neuropsychiatrische Symptomatik des sogenannten “Coma hepticum”. Wiener Klin Wochenschr 93: 3–19Google Scholar
  18. 17.
    Birchner J, Haemmerli UP, Scollo-Lavizzari G, Hoffmann K (1971) Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature. Am J Med 51: 148–159Google Scholar
  19. 18.
    Blume U, Helmstaedt D, Sybrecht G et al. (1976) Haemoperfusion therapy of acute hepatic failure. Dtsch Med Wochenschr 101: 559–565PubMedGoogle Scholar
  20. 19.
    Brown CL, Hill MJ, Richards P (1971) Bacterial ureases in uraemic men. Lancet 11: 406–409Google Scholar
  21. 20.
    Bruijn KM, Blendis LM, Zilm DH, Carlen PL, Anderson GH (1983) Effect of dietary protein manipulations in subclinical portal-systemic encephalopathy. Gut 24: 53–60PubMedGoogle Scholar
  22. 21.
    Brunner G, Losgen H (1983) Plasma exchange in liver disease. In: Gurland HJ, Lysaght MJ (ed) Plasma separation and plasma fractionation. Karger, Basel, pp 115–123Google Scholar
  23. 22.
    Burnell JM, Dawborn JK, Epstein RB, Guthman RA, Leinbach GE, Thomas ED, Volwiler W (1967) Acute hepatic coma treated by cross-circulation or exchange transfusion. N Engl J Med 276: 935–943PubMedGoogle Scholar
  24. 23.
    Canalese J, Gimson AES, Davis C et al. (1982) Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 23: 625–629PubMedGoogle Scholar
  25. 24.
    Cangiano C, Farber MO, Cardielli-Cangiano P et al. (1982) Plasma levels of false neurotransmitters across the brain in portal-systemic encephalopathy. Euro J Clin Invest 12: 15 - 21Google Scholar
  26. 25.
    Capocaccia L, Cangiano C, Attili AF, Angelico M, Cascino A, Rossi-Fanelli F (1977) Octopamine and ammonia plasma levels in hepatic encephalopathy. Clin Chim Acta 75: 99–105PubMedGoogle Scholar
  27. 26.
    Carakushansky G, Neu RL, Gardner LI (1969) Plasmapheresis in hepatic coma. Lancet 1: 152–153Google Scholar
  28. 27.
    Cascino A, Cangiano C, Calcaterra V, Rossi-Fanelli F, Capocaccia L (1978) Plasma amino acids imbalance in patients with liver disease. Am J Dig Dis 23: 591–598PubMedGoogle Scholar
  29. 28.
    Caulaert C, Deviller Ch, Halff M (1932) Troubles provoques par l’ingestion de sels amoniacaux chez l’homme attent de cirrhose de laennec. C R Soc Biol 111:739– 742Google Scholar
  30. 29.
    Cerra FB, Cheung NK, Kaplowitz JEN et al. (1985) Disease-specific amino acid infusion (F080) in hepatic encephalopathy: A prospective randomized, double-blind, controlled trial. OPEN 9: 288–295Google Scholar
  31. 30.
    Chase RA, Davies M, Trewby PN, Silk DBA, Williams R (1978) Plasma amino acid profiles in patients with fulminant hepatic failure treated by repeated polyacrylonitrile membrane hemodialysis. Gastroenterology 75: 1033–1040PubMedGoogle Scholar
  32. 31.
    Christie ML, Sack DM, Pomposelli J, Horst D (1985) Enriched branched-chain amino acid formula versus a casein-based supplement in the treatment of cirrhosis. Parenter Enteral Nutr 9: 671–678Google Scholar
  33. 32.
    Conn HO, Floch MH (1970) Effects of lactulose and lactobacillus acidophilus on the fecal flora. Am J Clin Nutr 23: 1588–1594PubMedGoogle Scholar
  34. 33.
    Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Madrey WC, Seeff L, Levy LL (1977) Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double-blind controlled trial. Gastroenterology 72: 573–583PubMedGoogle Scholar
  35. 34.
    Conn HO, Lieberthal MM (1979) The hepatic coma syndrome and lactulose. Williams amp; Wilkins, BaltimoreGoogle Scholar
  36. 35.
    Cordopatri F, Boncinelli S, Marsiii M et al. (1982) Effects of charcoal haemoperfusion with prostacyclin on the coagulation-fibrinolysis system and platelets of patients with fulminant hepatic failure — preliminary observation. Int J Artif Organs 5: 243–247PubMedGoogle Scholar
  37. 36.
    Crossley IR, Williams R (1984) Progress in the treatment of chronic portasystemic encephalopathy. Gut 25: 85–98PubMedGoogle Scholar
  38. 37.
    Cuilleret G, Pomier-Layrargues G, Pons F, Cadilhac J, Michel H (1980) Changes in brain catecholamine levels in human cirrhotic hepatic encephalopathy. Gut 21:565– 569PubMedGoogle Scholar
  39. 38.
    Dawson AM, McLaren J, Sherlock S (1957) Neomycin in the treatment of hepatic coma. Lancet 11: 1263–1268Google Scholar
  40. 39.
    Denis J, Opolon P, Nusinovici V, Granger A, Darnis F (1978) Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane. Gut 19: 787–793PubMedGoogle Scholar
  41. 40.
    Dibilidox M, Uribe M, Malpica S, Guillermo E, Villallobos A, Garcia-Ramos G (1985) Successful use of dietary fiber for the treatment of hepatic encephalopathy and diabetes. Hepatology 3: 331 (Abstract)Google Scholar
  42. 41.
    Dodsworth JM, Cummings MG, James JH, Fischer JE (1974) Decreased brain nore-pinephrine in acute hepatic coma. Gastroenterol 66: 881Google Scholar
  43. 42.
    Drasar BS, Hill MJ (1974) Human intestinal flora. Academic, London, pp 90–94Google Scholar
  44. 43.
    Durden WD, Siemsen AW, Briggs WA (1969) Exchange transfusions in the treatment of fulminant hepatitis and coma. Am J Gastroenterol 51: 129–137PubMedGoogle Scholar
  45. 44.
    European Association for the study of the liver (1979) Randomised trial of steroid therapy in acute liver failure. Gut 20: 620–623Google Scholar
  46. 45.
    Eckert P, Liehr H (1981) Akutes und chronisches Leberversagen. Thieme, StuttgartGoogle Scholar
  47. 46.
    Ede RJ, Williams R (1986) Hepatic encephalopathy and cerebral edema. Semin Liver Dis 6: 107–118PubMedGoogle Scholar
  48. 47.
    Egberts E-H, Hamster W, Schomerus H, Jürgens P (1982) Beeinflussung der latenten PSE durch orale Zufuhr verzweigtkettiger Aminosäuren, eine Doppelblind-crossover- Studie. Verh Dtsch Ges Inn Med 88: 1043–1046Google Scholar
  49. 48.
    Egberts E-H, Schomerus H, Hamster W, Jürgens P (1982) Effekt von parenteralen Aminosäurenlösungen auf die latente PSE. Randomisierte, einfach blinde Cross- over-Studie mit psychometrischen Untersuchungen. In: Holm E (Hrsg) Aminosäuren- und Ammoniakstoffwechsel bei Leberinsuffizienz. Witzstrock, Baden-Baden, S 184– 192Google Scholar
  50. 49.
    Eisenburg J (1986) Coma hepaticum. In: Hornbostel H, Kaufmann W, Siegenthaler W (Hrsg) Innere Medizin in Praxis und Klinik. (Bd IV, 3. Aufl. Thieme, Stuttgart, S 15.306–15. 322Google Scholar
  51. 50.
    Elithorn A, Lunzer M, Weisman J (1975) Cognitive deficits associated with chronic hepatic encephalopathy and their response to Levodopa. J Neurol Neurosurg Psychiatr 38: 794–798PubMedGoogle Scholar
  52. 51.
    Elkington SG, Floch MH, Conn HO (1969) Lactulose in the treatment of chronic portal-systemic encephalopathy: a double-blind clinical trial. N Engl J Med 281:408– 412Google Scholar
  53. 52.
    Eriksson LS, Persson A, Wahren J (1982) Branched-chain amino acids in the treatment of chronic hepatic encephalopathy. Gut 23: 801–806PubMedGoogle Scholar
  54. 53.
    Faraj BA, Camp VM, Ansley JD, Scott J, Ali FM, Malveaux EJ (1981) Evidence of central hypertyraminemia in hepatic encephalopathy. J Clin Invest 67: 395–402PubMedGoogle Scholar
  55. 54.
    Fenton JCB, Knight EJ, Humpherson PL (1966) Milk-and-cheese diet in portal-systemic encephalopathy. Lancet 1: 164–166PubMedGoogle Scholar
  56. 55.
    Fessel JM, Conn HO (1973) Lactulose in the treatment of acute hepatic encephalopathy. Am J Med Sci 266: 103–110PubMedGoogle Scholar
  57. 55a.
    Fiaccadori F, Ghinelli F, Pedretti G et al. (1985) Branched-chain enriches amino acid solutions in the treatment of hepatic encephalopathy: a controlled trial. Ital J Gastroenterology 17: 5–10Google Scholar
  58. 56.
    Fischer JE (1985) Portal-systemic encephalopathy. In: Wright R, Millward-Sadler GH, Alberti KGMM, Karren S (eds) Liver and biliary disease, 2nd edn. Bailliere Tindall Saunders, London, pp 1276–1273Google Scholar
  59. 57.
    Fischer JE, Baldessarini RJ (1971) False neurotransmitters and hepatic failure. Lancet 11: 75–80Google Scholar
  60. 58.
    Fischer JE, Funovics JM, Falcao HA, Wesdorp RIC (1976) L-Dopa in hepatic coma. Ann Surg 183: 386–391PubMedGoogle Scholar
  61. 59.
    Fräser CL, Arieff AI (1985) Hepatic encephalopathy. N Engl J Med 313: 865–873PubMedGoogle Scholar
  62. 60.
    Freeman JG, Bassendine M, Health P, James OFW, Record CO (1983) Double blind trial of branched chain amino acid infusions in cases of hepatic encephalopathy. Gut 24: 73 (Abstract)Google Scholar
  63. 61.
    Gazzard BL, Clark R, Boriakchanyavat V, Williams R (1974) A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis. Gut 15: 89–93PubMedGoogle Scholar
  64. 62.
    Gazzard BL, Portmann B, Murray-Lyon IM, Williams R (1975) Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. Q J Med 44: 615PubMedGoogle Scholar
  65. 63.
    Gelfand MC, Winchester JF, Knepshield JH et al. (1978) Biochemical correlations of reversal of hepatic coma treated with charcoal haemoperfusion. Trans Am Soc Artif Intern Organs 24: 239–242PubMedGoogle Scholar
  66. 64.
    Gelfand MJ, Sussman L, Caimol BC, Florita C, Jonson F (1967) Successful treatment of hepatic coma by exchange transfusions. J Am M Assoc 201: 630–633Google Scholar
  67. 65.
    Germain L, Frexinos J, Louis A, Ribet A (1973) Effect of lactulose on postshunt hepatic. A controlled trial. Arch Fr Mai App Dig 62: 293–301Google Scholar
  68. 66.
    Gerok W (1985) Metabolische Grundlagen der hepatischen Encephalopathie. Internist 26: 377–387PubMedGoogle Scholar
  69. 67.
    Giinson AES, Braude S, Mellon PJ et al. (1982) Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 11: 681–683Google Scholar
  70. 68.
    Goldberg M, Strecker W, Feeny D, Ruhenstroth-Bauer G (1980) Evidence for and characterisation of a liver cell proliferation factor from blood plasma of partially hepaectomised rats. Horm Metab Res 12: 94–96PubMedGoogle Scholar
  71. 69.
    Gregory PB, Knauer CM, Kempson RL, Miller R (1976) Steroid therapy in severe viral hepatitis. N Engl J Med 294: 681–687PubMedGoogle Scholar
  72. 70.
    Greenberger NJ, Carley JE, Schenker S, Bettinger I, Stamnes C, Beyer P (1977) Effect of vegetable and animal protein diets in chronic hepatic encephalopathy. Am J Dig Dis 22: 845–855PubMedGoogle Scholar
  73. 71.
    Guarnieri GF, Toigo G, Situlin R, Pozzato G, Faccini L et al. (1984) Muscle biopsy studies on malnutrition in patients with liver cirrhosis: preliminary results of long-term treatment with a branched-chain amino acid enriched diet. In: Capocaccia L, Fischer JE, Rossi-Fanelli F (eds) Hepatic encephalopathy in chronic liver failure. Plenum, New York, pp 193–208Google Scholar
  74. 72.
    Hahn M, Massen O, Nencki M, Pawlow J (1893) Die Eck’sche Fistel zwischen der unteren Hohlvene und der Pfortader und ihre Folgen für den Organismus. Arch Exp Pathol Pharmakol 32: 161–210Google Scholar
  75. 73.
    Hawley K, Morgan MY (1986) Randomised controlled double blind trial of lactitol and lactulose in acute hepatic encephalopathy in cirrhotic patients. Gut 27Google Scholar
  76. 73.
    a. Ftenderson JM, Millikan WJ, Warren WD (1982) Manipulation of the amino acid profile in cirrhosis with hepatic aid or F080 to reverse encephalopathy. Hepatology 2: (Abstract 133)Google Scholar
  77. 74.
    Herlong HF, Maddrey WC, Walser M (1980) The use of ornithine salts of branched- chain ketoacids in portal-systemic encephalopathy. Ann Intern Med 93: 545–550PubMedGoogle Scholar
  78. 75.
    Hickman R, Saunders SJ, King JB, Harrison GG, Terblanche J (1971) Pig liver perfusion in the treatment of fulminant hepatic necrosis. Scand J Gastroenterol 6: 563–568Google Scholar
  79. 76.
    Hörtnagl H, Lochs H, Kleinberger G, Hackl JM, Hammerle AF, Binder H, Wewalka F: Plasma catecholamine. Klin Wochenschr 59: 1159–1164Google Scholar
  80. 77.
    Holdsworth JD, Dianigi P, Clague, MB, James OFW, Wright PD (1984) Body protein metabolism and plasma amino acids in cirrhosis of the liver. The effect of varying the branched chain amino acid content of intravenous amino acid solutions. Clin Nutr 3: 153–162Google Scholar
  81. 78.
    Holm E, Staedt U, Leweling H, Bäßler KH, Specker M, Tschepe A (1983) Fettstoff–wechsel und parenterale Fettzufuhr bei Leberinsuffizienz. Infusionstherapie 10: 184–204Google Scholar
  82. 79.
    Horst D, Grace ND, Conn HO, Schiff E, Schenker S, Viteri A, Law D, Atterbury CE (1983) Comparison of dietary protein with an oral, branched chain-enriched amino acids supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology 4: 279–287Google Scholar
  83. 80.
    Hughes R, Williams R (1986) Clinical experience with charcoal and resin hemoperfusion. Semin Liver Dis 6: 164–173PubMedGoogle Scholar
  84. 81.
    Hutson DG, Ono J, Dombro RS, Levi JU, Livingstone A, Zeppa R (1979) A longitudinal study of tryptophan involvement in hepatic coma. Am J Surg 137: 235–239PubMedGoogle Scholar
  85. 82.
    Imler M, Kurtz D, Bockel R, Stahl J (1971) Comparative study of the treatment of portocaval encephalopathy with lactulose, lactic bacilli and antibiotics. Therapeutique 47: 237–248PubMedGoogle Scholar
  86. 83.
    Inoue N, Yoshiba M, Yamakazi Z et al. (1981) Continuous flow membrane plasma-pheresis utilizing cellulose acetate hollow fibre in hepatic failure. In: Brunner G, Schmidt FW, (eds) Artificial liver support. Springer, Berlin Heidelberg New York, pp 175–180Google Scholar
  87. 84.
    Jeppson B, Kjällman A, Oslund U, Alwmark A, Gullstrand P, Joelsson B (1983) Effect of vegetable and mixed protein diets in mild chronic portal systemic encephalopathy (PSE). European Society for Parenteral and Enteral Nutrition 1983, (Abstract)Google Scholar
  88. 85.
    Jones EA, Clain D, Clink HM, MacGillivray MM, Sherlock S (1967) Hepatic coma due to acute hepatic necrosis treated by exchange blood transfusion. Lancet 11: 169–172Google Scholar
  89. 86.
    Jouboud F, Chauveau P, Fresneau M et al. (1974) Le traitement du coma hepatique par L-dopa. A propos de 22 cas. Arch Fr Mal App Dig 63: 164–165Google Scholar
  90. 87.
    Kennedy HJ, Greaves M, Triger DR (1985) Clinical experience with use of characoal haemoperfusion: is prostacyclin required? Life Supp Syst, 3: 115–122Google Scholar
  91. 88.
    Keshavarzian A, Meek J, Sutton C, Emery VM, Hughes EA, Hodgson HJF (1984) Dietary protein supplementation from vegetable sources in the management of chronic portal systemic encephalopathy. Am J Gastroenterol, 79: 945–949PubMedGoogle Scholar
  92. 89.
    Klebanoff G, Armstrong RG, Cline RE (1972) Resuscitation of a patient in stage IV hepatic coma using total body washout. J Surg Res 13: 159–165PubMedGoogle Scholar
  93. 90.
    Kleinberger G, Kotzaurek R, Pall H, Pichler M, Szeless S (1976) Parenterale Ernährung bei Coma hepaticum. Leber Magen Darm 6: 340–346PubMedGoogle Scholar
  94. 91.
    Kleinberger G (1978) Parenterale Ernährung beim Coma hepaticum. Infusionsther Klin Ernähr 1: 193–209Google Scholar
  95. 92.
    Korge M (1986) Influence of an oral aminoacid-mixture on the plasma amino acid of cirrhotic patients with portacaval shunt. Dig Dis Sci 31 [Suppl] (Abstract 519)Google Scholar
  96. 93.
    Krummenerl T, Lohmann J, Kamanabroo D, Pott G, Wawerka J, Gerlach U (1983) Behandlung des akuten Leberversagens durch Plasmapherese. Dtsch Med Wochenschr 108: 261–266PubMedGoogle Scholar
  97. 94.
    Langer M, Masala A, Alagna S, Rassu S, Madeddu G, Solinas A, Chiandussi L (1981) Growth hormone ( GH) secretion in hepatic encephalopathy. Clin Endocrinology 4: 189–192Google Scholar
  98. 95.
    Langhans E, Holm E, Staedt U, Harmann M (1981) Diätetische Anwendung verzweigtkettiger Aminosäuren bei Patienten mit Leberzirrhose. Eine kontrollierte Untersuchung biochemischer und psychometrischer Parameter sowie des EEG. Z Gastroenterol 19:495 AGoogle Scholar
  99. 96.
    Lanzinger G, Kommereil B (1974) Levodopa-Therapie beim hepatischen Koma. Dtsch Med Wochenschr 99: 700–705PubMedGoogle Scholar
  100. 97.
    Ledermann RJ, Davies FB, Davies PJ (1968) Exchange transfusion as treatment of acute hepatic failure due to antituberculous drugs. Ann Intern Med 68: 830–838Google Scholar
  101. 98.
    Lee C, Tink A (1958) Exchange transfusion in hepatic coma. Report of a case. Med J Austr 1: 40Google Scholar
  102. 99.
    Leeuwen PA (1985) Ammonia generation in the Gut and the influence of lactulose and neomycin. Proefschrift, MaastrichtGoogle Scholar
  103. 100.
    Lepore MJ, Martel AJ (1970) Plasmapheresis with plasma exchange in hepatic coma. Methods and results in five patients with acute fulminant hepatic necrosis. Ann Intern Med 72: 165–174Google Scholar
  104. 101.
    Lie TS (1981) Treatment of acute and hepatic failure by extracorporal haemoperfusion over human and baboon liver. In: Brunner G, Schmidt FW (eds) Artificial liver support. Springer, Berlin Heidelberg New York, pp 268–273Google Scholar
  105. 102.
    Lie TS, Dengler HJ, Gütgemann A et al. (1977) Die extrakorporale Perfusion mit Pavianlebern zur Behandlung des Leberzerfallskomas. Dtsch Med Wochenschr 102: 1506–1511PubMedGoogle Scholar
  106. 102.
    a. Lunzer M, James IM, Weinmann J, Sherlock S (1974) Treatment of chronic hepatic encephalopathy with levodopa. Gut 15: 555–561Google Scholar
  107. 103.
    Ma MH, McLeod JG, Blackburn CRB (1969) Long-treatment of portal-systemic en-cephalopathy with lactulose. Aust Ann Med 18: 117–123PubMedGoogle Scholar
  108. 104.
    Macbeth WAAG, Kass EH Jr, McDermott WV (1965) Treatment of hepatic encephalopathy by alteration of intestinal flora with lactobacillus acidophilus. Lancet 1: 399–403PubMedGoogle Scholar
  109. 105.
    MacDougall BRD, Bailey RJ, Williams R (1972) H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Lancet 1: 617–619Google Scholar
  110. 106.
    Manghani KK, Lunzer MR, Billing BH, Sherlock S (1975) Urinary and serum octopamine in patients with portal-systemic encephalopathy. Lancet 11: 943–946Google Scholar
  111. 107.
    Marin GA, Montoya CA, Sierra JL, Senior JR (1971) Evaluation of corticosteroid and exchange transfusion treatment of acute yellow-phosphorous intoxication. N Engl J Med 284: 125–128PubMedGoogle Scholar
  112. 107a.
    Marchesini G, Bianchi GP, Zoli M et al. (1987) BCAA oral nel trattamento dell encephalopatia epatica. 5. Nationaler Kongreß der italienischen Gesellschaft für künstliche Ernährung. Triest, Oktober, 1987Google Scholar
  113. 108.
    Marsh WH, Block KP (1985) A comparative evaluation of a branched-chain amino acid enriched diet in stable cirrhosis. American Association for the Study of Liver Disease (Abstract 352 )Google Scholar
  114. 109.
    McClain CJ, Kromhout JP, Elson MK, Van Thiel DH (1981) Hyperprolactinemia in portal systemic encephalopathy. Dig Dis Sci 26: 353–357PubMedGoogle Scholar
  115. 110.
    McDermott WV, Adams RD (1954) Episodic stupor associated with an Eck fistula in the human with particular reference to the metabolism of ammonia. J Clin Invest 33: 1–9PubMedGoogle Scholar
  116. 111.
    McGhee A, Henderson JM, Millikan WJ, Bleider JC, Vogel R, Kassouny M, Rudman D (1983) Comparison of the effects of hepatic-acid and a casein modular diet on encephalopathy, plasma amino acids, and nitrogen balance in cirrhotic patients. Ann Surg 197: 288–293PubMedGoogle Scholar
  117. 112.
    McKechnie JC, Hersh T (1971) Exchange transfusion in hepatic coma. A review of 19 cases. Am J Gastroenterol 56: 17–43PubMedGoogle Scholar
  118. 113.
    Michel H, Solere M, Granier P, Cauvet G, Bali JP, Pons F, Bellet-Hermann H (1980) Treatment of cirrhotic hepatic encephalopathy with L-Dopa. A controlled trial. Gastroenterology 79: 207–211Google Scholar
  119. 114.
    Michel H, Bories P, Aubin JP, Pomier-Layrargues G, Bauret P, Bellet-Herman H (1985) Treatment of acute hepatic encephalopathy in cirrhotics with a branched chain amino acids enriched versus a conventional amino acids mixture. A controlled study of 70 patients. Liver 5: 282–289PubMedGoogle Scholar
  120. 115.
    Morgan MY, Milsom JP, Sherlock S (1978) Plasma ratio of valine, leucine, and isoleucine to phenylalanine and tyrosine in liver disease. Gut 19: 1068–1073PubMedGoogle Scholar
  121. 116.
    Morgan MY, Jakobovits AW, James IM, Sherlock S (1980) Successful use of bro-mocriptine in the treatment of chronic hepatic encephalopathy. Gastroenterology 78: 663–670PubMedGoogle Scholar
  122. 117.
    Morgan MH, Read AE, Speller DCE (1982) Treatment of hepatic encephalopathy with metronidazole. Gut 23: 1–7PubMedGoogle Scholar
  123. 118.
    Müting D (1979) Auslösende Faktoren und klinisches Bild des Leberkomas bei 152 Leberzirrhosepatienten. MMW 121: 453–456Google Scholar
  124. 119.
    Müting D, Reikowski J, Leimbeck R, Flaßhoff H-J, Rausche A (1983) Untersuchungen über die Wirkung einer Bacteriumbifidum-Milch auf Darmflora und Leberfunktion. Therapiewoche 33: 6856–6865Google Scholar
  125. 120.
    Müting D, Koussouris P, Paquet KP (1984) Nutrition in acute and chronic liver diseases with consideration of the protein tolerance. In: Holm E, Kasper H (eds) Metabolism and nutrition in liver disease. Falk Symposium, Freiburg. MTP Press, Lancaster, pp 369–380Google Scholar
  126. 121.
    Müting D, Kalk JF, Stössel-Kirchner C, Feussner H (1985) Kontrollierte Studie über die Wirkung hoher Natriumacetat-Puffer-Einläufe bei hepatischer Enzephalopathie. Z Gastroenterol 23: 374Google Scholar
  127. 122.
    Müting D (1986) Pathogenese und Klinik der hepatischen Enzephalopathie. Therapiewoche 36 /7: 587–596Google Scholar
  128. 123.
    Nespoli A, Bevilacqua G, Staudacher C, Rossi N, Salerno F, Castelli MR (1981) Pathogenesis of hepatic encephalopathy and hyperdynamic syndrome in cirrhosis. Arch Surg 116: 1129–1138PubMedGoogle Scholar
  129. 124.
    Okita M, Watanabe A, Nagashima H (1985) Nutritional treatment of liver cirrhosis by branched-chain amino acid-enriched nutrient mixture. J Nutr Sei Vitaminol (Tokyo) 31: 291–303Google Scholar
  130. 125.
    Ossorio Castellanos C, Noguera Hernando E, Isaria Muñoz T (1974) La utilización de L-dopa en el tratamiento del coma hepático. Rev Esp Enferm Apar Dig 43: 563–572Google Scholar
  131. 126.
    Paigen K, Williams B (1970) Catabolite repression and other control mechanismus in carbohydrate utilization. Adv Microb Physiol 4: 251–324Google Scholar
  132. 127.
    Parbroo SP, Chalstrey LJ, Ajdukiewicz AB, James JM, Hillenbrandt P, Kennedy J (1971) Extracorporeal perfusion of pig liver in the treatment of acute liver failure. Br J Surg 58: 746–748Google Scholar
  133. 128.
    Parkes JD, Sharpstone P, Williams R (1970) Levodopa in hepatic coma. Lancet 11: 1341–1343Google Scholar
  134. 129.
    Phear EA, Ruebner B, Sherlock S, Summerskill WHJ (1957) Methionine toxicity in liver disease and its prevention by Chlortetracycline. Clin Sci 15: 93–117Google Scholar
  135. 130.
    Pirotte J, Guffens JM, Devos J (1974) Comparative study of basal arterial ammonaemia and of orally-induced hyperammonaemia in chronic portal systemic encephalopathy treated with neomycin, lactulose and association of neomycin and lactulose. Digestion 10: 435–444PubMedGoogle Scholar
  136. 131.
    Plauth M, Brunner I, Graser T, Fürst P, Hartmann F (1986) Der isoliert vaskulär und luminal perfundierte Rattendünndarm als Modell zur Untersuchung der intestinalen Ammoniogenese. 5. Gemeinsame Jahrestagung der deutschen und österreichischen Arbeitsgemeinschaften für künstliche Ernährung, SalzburgGoogle Scholar
  137. 132.
    Pott G, Kamanabroo D, Krummenerl T, Lohmann J, Gerlach U (1983) Therapie des akuten Leberversagens. Dtsch Med Wochenschr 108: 1327–1329PubMedGoogle Scholar
  138. 133.
    Peleman RR, Gavaler RR, van Thiel DJ, Starzl TE (1985) Liver transplantation for acute and subacute hepatic failure. Hepatology 5: 1045 (Abstract)Google Scholar
  139. 134.
    Rakela J, Redeker AG, Edwards VM, Decker R, Oberby LR, Mosley JW (1978) Hepatitis-A virus infection in fulminant hepatitis and chronic active hepatitis. Gastroenterology 74: 879PubMedGoogle Scholar
  140. 135.
    Read AE, Sherlock S, Laidlaw J, Walker JG (1967) The neuropsychiatric syndromes associated with chronic liver disease and an extensive portal-systemic collateral circulation. Q J Med 36: 135–150Google Scholar
  141. 136.
    Read AE, McCarthy CF, Heaton KW, Laidlaw J (1966) Lactobacillus acidophilus ( Enpac) in treatment of hepatic encephalopathy. Br Med J 1: 1267–1269Google Scholar
  142. 137.
    Redeker AG, Yamahiro HS (1973) Controlled trial of exchangetransfusion therapy in fulminant hepatitis. Lancet 1: 3–6PubMedGoogle Scholar
  143. 138.
    Redeker AG, Schweitzer IK, Yamahiro HS (1976) Randomization of corticosteroid therapy in fulminant hepatitis. N Engl J Med 294: 728–729PubMedGoogle Scholar
  144. 139.
    Riederer P, Jellinger K, Rausch WD, Kleinberger G, Kothbauer P (1978) Zur Bio¬chemie der hepatischen Enzephalopathie. Z Gastroenterol 12: 768–777Google Scholar
  145. 140.
    Riederer P, Jellinger K, Kleinberger G, Weiser M (1980) Oral and parenteral nutrition with L-valine: mode of action. Nutr Metab 24: 209–217PubMedGoogle Scholar
  146. 141.
    Riggio O, Cangyno C, Cascino A, Merli M, Stortonie M et al. (1984) Long term dietary supplement with branched chain amino acids: a new approach in the prevention of hepatic encephalopathy: results of a controlled study in cirrhotics with portocaval anastomosis. In: Capocaccia L, Fischer JE, Rossi-Fanelli F (eds) Hepatic encephalopa¬thy in chronic liver failure. Plenum, New York, pp 183–192Google Scholar
  147. 142.
    Rocchi E, Cassanelli M, Gibertini P, Pietrangelo A, Casalgrandi G, Ventura E (1985) Standard or branched-chain amino acid infusions as short-term nutritional support in liver cirrhosis? J Parenter Enteral Nutr 9: 447–451Google Scholar
  148. 143.
    Rössle M, Herz R, Lehmann G, Luft M, Gerok W (1982) Therapie der hepatischen Enzephalopathie. Infusionstherapie 9: 256–258Google Scholar
  149. 144.
    Rosa H, Melo-Souza SE (1976) Therapie der hepatischen Enzephalopathie mit L-dopa. (Portugiesisch) Azq Gastroenterol 13: 147–152Google Scholar
  150. 145.
    Rossi-Fanelli F, Cangiano C, Attilli A et al. (1976) Octopamine plasma levels and hepatic encephalopathy. A reappraisal of the problem. Clin Chim Acta 67: 255–261PubMedGoogle Scholar
  151. 146.
    Rossi-Fanelli F, Riggio O, Cangiano C, Cascino A, de Conciliis D, Merli M, Stortoni M, Giunchi G (1982) Branched-chain amino acids vs lactulose in the treatment of hepatic coma. A controlled study. Dig Dis Sci 27: 929–935PubMedGoogle Scholar
  152. 147.
    Sabbaj J, Sutter VL, Finegold SM (1970) Urease and deaminase activities of faecal bacteria in hepatic coma. Antimicrobiol Chemotherapy 16: 181–185Google Scholar
  153. 148.
    Sabin S, Merritt JA (1968) Treatment of hepatic coma in cirrhosis by plasmapheresis and plasma infusions. Ann Intern Med 68: 1–7PubMedGoogle Scholar
  154. 149.
    Sarrazin A, Emerit J, Olivier L et al. (1971) Traitement du coma hepatique par la L-dopa. Premiers resultats. Nouv Presse Med 79: 2226–2227Google Scholar
  155. 150.
    Saunders SJ, Bosmann SCW, Barnard CN, Terblanche J (1970) Austauschtransfusionen und Kreuzzirkulation mit Pavianen bei der Behandlung des akuten Leberversagens. Internist 11: 77–84PubMedGoogle Scholar
  156. 151.
    Scotto JP, Opolon P, Eteve J, Vergoz D, Thomas M, Caroli J (1973) Liver biopsy and prognosis in acute liver failure. Gut 14: 927PubMedGoogle Scholar
  157. 152.
    Shaw S, Worner TM, Lieber CS (1983) Comparison of animal and vegetable protein sources in the dietary management of hepatic encephalopathy. Am J Clin Nutr 38:59— 63Google Scholar
  158. 153.
    Shearman DJC, Finlayson NDC (1982) Diseases of the gastrointestinal tract and liver. Churchill Livingstone, EdinburghGoogle Scholar
  159. 154.
    Sherlock S, Summerskill WHJ, Dawson AM (1956) The treatment and prognosis of hepatic coma. Lancet 11: 689–694Google Scholar
  160. 155.
    Silen W, Harper HA, Mawdsley DL, Weirich WL (1955) Effect of antibacterial agents on ammonia production within the intestine. Proc Soc Exp Biol Med 88: 138–140PubMedGoogle Scholar
  161. 156.
    Sieg A, Walker S, Czygan P, Lanzinger-Rossnagel G, Stiehl A, Kommerell B (1983) Branched-chain amino acid-enriched elemental diet in patients with cirrhosis of the liver. A double blind crossover trial. Z Gastroenterol 21: 644–655Google Scholar
  162. 157.
    Simert G, Nobin A, Rosengren E, Vang J (1978) Neurotransmitter changes in the rat brain after portocaval anastomosis. Eur Surg Res 10: 73–85PubMedGoogle Scholar
  163. 158.
    Simko V (1983) Long-term tolerance of a special amino acid oral formula in patients with advanced liver disease. Nutr Rep Int 27: 765–773Google Scholar
  164. 159.
    Simmons F, Goldstein H, Boyle JD (1970) A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 59: 827–832PubMedGoogle Scholar
  165. 160.
    Smith III RB, Vorhees AB, Davidson EA, Barker HG (1964) Toxic effects of ingested whole proteins and amino acid mixtures in patients with portal systemic encephalopathy. Surg Forum 15: 98–99PubMedGoogle Scholar
  166. 161.
    Smith AR, Rossi-Fanelli F, Ziparo V, James JH, Perelle BA, Fischer JE (1978) Alterations in plasma and CSF amino acids, amines and metabolites in hepatic coma. Ann Surg 187: 343–350PubMedGoogle Scholar
  167. 162.
    Summerskill WHJ, Wolfe SJ, Davidson CS (1957) The management of hepatic coma in relation to protein withdrawal and certain specific measures. Am J Med 23:59– 76Google Scholar
  168. 163.
    Swart GR, Frenkel M, van den Berg J WO (1981) Minimum protein requirements in advanced liver disease: a metabolic ward study of the effects of oral branched chain amino acids. In: Walser H, Williamson JR (eds) Metabolism and clinical implications of branched chain amino and ketoacids. Elsevier/North-Holland, New York, pp 427– 432Google Scholar
  169. 164.
    Swift JE, Ghent WR, Beck JT (1967) Direct transhepatic cross-circulation in hepatic coma in man. Can Med Assoc J 17: 1435–1445Google Scholar
  170. 165.
    Schäfer K, Winther MB, Ukida M, Leweling H, Reiter HJ, Bode JC (1981) Influence of an orally administered protein mixture enriched in branched chain amino acids on the chronic hepatic encephalopathy ( CHE) of patients with liver cirrhosis. Z Gastroenterol 19: 356–362Google Scholar
  171. 166.
    Schauder P (1984) Therapeutische Bedeutung verzweigtkettiger Keto- und Aminosäuren. Internist 25: 313–319PubMedGoogle Scholar
  172. 167.
    Schomerus H, Hamster W, Blunck H, Reinhard U, Mayer K, Dölle W (1981) Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci 26: 622–630PubMedGoogle Scholar
  173. 168.
    Schomerus H (1986) Erscheinungsformen, Häufigkeit und Therapie der portokavalen Enzephalopathie. Therapiewoche 36: 1027–1030Google Scholar
  174. 169.
    Schwemmle K (1971) Behandlung des Leberkomas mit der heterologen Leberperfusion. MMW 113: 519–523Google Scholar
  175. 170.
    Strauss E, Santos WR, Cartapatti da Silva E, Lacet CM, Capacci MLL, Bernardini AP (1986) Treatment of hepatic encephalopathy: A randomized clinical trial comparing a branched chain enriched amino acid solution to oral neomycin. Nutr Supp Serv 6: 18–21Google Scholar
  176. 171.
    Tarao K, Ikeda T, Hayashi K, Sakurai A, Tsuchiya T, Ito T (1986) Therapeutic efficacy of vancomycin hydrochoride, a nonabsorbable antibiotics, on intractable (lactulose resistant) chronic hepatic encephalopathy in cirrhotic patients. Jpn J Gastroenterol 83: 1006–1014Google Scholar
  177. 172.
    Tarter RE, Sandford SS, Hays AL, van Thiel DH (1986) Cerebral morphological abnormalities associated with non-alcoholics cirrhosis. Lancet 11: 893–895Google Scholar
  178. 173.
    Trey C, Burns, DG, Saunders SJ (1966) Treatment of hepatic coma by exchance blood transfusion. N Engl J Med 274: 473–481PubMedGoogle Scholar
  179. 174.
    Trey C, Lipworth L, Davidson CS (1970) Parameters influencing survival in the first 318 patients reported to the fulminant hepatic failure surveillance study. Gastroenterology 58: 306Google Scholar
  180. 175.
    Tschepe A, Holm E, Leweling H, Staedt U, Weber K (1985) Oral administration of branched chain amino acids (BCAA) in patients with liver cirrhosis. A double-blind, randomized crossover study. European Society of Parenteral and Enteral NutritionGoogle Scholar
  181. 176.
    Tsuburaya T, Matsushita M, Kashimo I et al. (1982) Evaluation of XAD-4 hemoperfusion for hepatic failure. Hepatology 2: 118Google Scholar
  182. 177.
    GestrichenGoogle Scholar
  183. 178.
    Tygstrup N, Ranek L (1981) Fulminant hepatic failure. Clin Gastroenterol 10:191 –208Google Scholar
  184. 179.
    Ufer Ch, Dölle W, Martini GA (1966) Überlebensdauer und Prognose bei Kranken mit Leberkoma. Internist 7: 43–47PubMedGoogle Scholar
  185. 180.
    Uribe M, Farca A, Márquez MA, Garcia-Ramos G, Guevara L (1979) Treatment of chronic portal systemic encephalopathy with bromocriptine. A double-blind controlled trial. Gastroenterology 76: 1347–1351Google Scholar
  186. 181.
    Uribe M, Márquez MA, Garcia-Ramos G et al. (1980) Treatment of chronic portal systemic encephalopathy with lactose in lactase deficient patients. Dig Dis Sci 25:924– 928PubMedGoogle Scholar
  187. 182.
    Uribe M, Berthier JM, Lewis H et al. (1981) Lactulose enemas plus placebo tablets vs. Neomycin tablets plus starch enemas in acute portal systemic enzephalopathy. Gastroenterology 81: 101–106PubMedGoogle Scholar
  188. 183.
    Uribe M, Márquez MA, Garcia-Ramos G, Ramos-Uribe MH, Vargas F, Villalobos A, Ramos C (1982) Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets. Dig Dis Sci 27: 1109–1116PubMedGoogle Scholar
  189. 184.
    Uribe M, Garcia-Ramos G, Ramos M, Valverda C, Márquez MA, Farca A, Guevara L (1983) Standard and higher doses of bromocriptine for severe chronic portal-systemic encephalopathy. Am J Gastroenterol 78: 517–522PubMedGoogle Scholar
  190. 185.
    Uribe M, Dibilidox M, Malpica S et al. (1985) Beneficial effect of vegetable protein diet supplemented with psyllium plantago in patients with hepatic encephalopathy and diabetes mellitus. Gastroenterology 88: 901–907PubMedGoogle Scholar
  191. 185a.
    Uribe M, Campollo O, Vargas F et al. (1987) Acidifying enemas (Lactitol and Lactulose) vs. nonacidifying enemas (Tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized-trial. Hepatology 7: 639–644PubMedGoogle Scholar
  192. 186.
    Victor M, Adams RD, Cole M (1965) The acquired (non-Wilsonian) type of chronic hepato-cerebral degeneration. Medicine 44: 345–396PubMedGoogle Scholar
  193. 187.
    Vilstrup H,Gluud C, Hardt F (1985) Branched chain enriched amino acid infusion to patients with hepatic encephalopathy. J Hepatology [Suppl 27] (Abstract 337 )Google Scholar
  194. 188.
    Vince A, Zeegen R, Drinkwater JE, O’Grady F, Dawson AM (1974) The effect of lactulose on the fecal flora of patients with hepatic encephalopathy. J Med Microbiol 7: 163–168PubMedGoogle Scholar
  195. 189.
    Vince A, Killingley M, Wrong OM (1978) Effect of lactulose on ammonia production in a fecal incubation system. Gastroenterology 74: 544–549PubMedGoogle Scholar
  196. 190.
    Vince A, Burridge SM (1980) Ammonia production by intestinal bacteria: the effects of lactose, lactulose, and glucose. J Med Microbiol 13: 177–191PubMedGoogle Scholar
  197. 191.
    Wahren J, Denis J, Desurmont P et al. (1983) Is intravenous administration of branched chain amino acids effective in the treatment of hepatic encephalopathy? A multicenter study. Hepatology 3: 475–480PubMedGoogle Scholar
  198. 192.
    Walker S, Götz R, Czygan P et al. (1982) Oral ketoanalogs of branched chain amino acids in hyperammonemia in patients with cirrhosis of the liver. A double-blind crossover study. Digestion 24: 105–111PubMedGoogle Scholar
  199. 193.
    Walser M (1984) Therapeutic aspects of branched-chain amino and keto acids. Clin Sci 66: 1–15PubMedGoogle Scholar
  200. 194.
    Ware AJ, D’Agostino A, Combes B (1971) Cerebral oedema: A major complication of massive hepatic necrosis. Gastroenterology 61: 877–884PubMedGoogle Scholar
  201. 195.
    Ware AJ, Jones RE, Shorey JW, Combes B (1974) A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol 62: 130–133PubMedGoogle Scholar
  202. 196.
    Weber FL (1979) The effect of lactulose on urea metabolism and nitrogen excretion in cirrhotic patients. Gastroenterology 77: 518–523PubMedGoogle Scholar
  203. 197.
    Weber FL, Fresard KS (1981) Comparative effects of lactulose and magnesium sulfate on urea metabolism and nitrogen balance in cirrhotic subjects. Gastroenterology 80: 994–998PubMedGoogle Scholar
  204. 198.
    Weber FL, Fresard KM, Lally BR (1982) Effects of lactulose and neomycin on urea metabolism in cirrhotic subjects. Gastroenterology 82: 213–217PubMedGoogle Scholar
  205. 199.
    Weber FL (1984) Hepatic encephalopathy. Gastroenterology 4: 197–237Google Scholar
  206. 200.
    Williams R, Silk DBA (1977) Kritischer Überblick über die Kohle-Hämoperfusion beim akuten Leberversagen. Hepatologie Akt 16: 5–11Google Scholar
  207. 201.
    Young PC, Burnside CR, Knowles HC, Schiff L (1957) The effects of intragastric administration of whole blood on the concentration of blood ammonia in patients with liver disease. J Lab Clin Med 50: 11–16PubMedGoogle Scholar
  208. 202.
    Yoshida K, Hirayama C (1980) Clinical evaluation of serum levels of tryptophan in hepatobiliary disease. Clin Chim Acta 101: 235–240PubMedGoogle Scholar
  209. 203.
    Zeegen R, Drinkwater JE, Fenton JCB, Vince A, Dawson AM (1970) Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy. Q J Med 39: 245–263PubMedGoogle Scholar
  210. 204.
    Zieve L, Mendelson DF, Goepfert M (1960) Shunt encephalopathy. II. Occurrence of permanent myelopathy. Ann Intern Med 53: 53–63PubMedGoogle Scholar
  211. 205.
    Zieve L, Doizaki WM, Zieve FJ (1974) Synergism between mercaptans and ammonia or fatty acids in the production of coma: a possible role for mercaptans in the pathogenesis of hepatic coma. J Lab Clin Med 83: 16–28PubMedGoogle Scholar
  212. 206.
    Zieve L, Olsen RL (1977) Can hepatic coma be caused by a reduction of brain noradrenalin or dopamine? Gut 18: 688–691PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • E.-H. Egberts

There are no affiliations available

Personalised recommendations